Opinion & analysis

New Age Thinking: US FDA’s Temple Sees Third Era Of Drug Development

Robert Temple, the FDA’s voice of institutional memory, believes drug regulation has quietly entered a third era: the “Age of Individualization.” Unlike the prior eras of safety and efficacy, there is no milestone legislation to set the ground rules. But, Temple stressed, there have been significant changes in areas like the assessment of drug-drug interactions, metabolic response to therapeutics, and in the FDA’s willingness for sub-population analyses. Is there a change in the air that will result in further change in drug development as it relates to the Age of the Individual?

New Age Thinking: US FDA’s Temple Sees Third Era Of Drug Development

US FDA’s Rush Following Novartis’ Delay Suggests Strong Displeasure With Handling Of Zolgensma Data Manipulation

FDA’s Withdrawn Reg On Data Fraud Hangs Over Zolgensma Incident

Contamination In Common OTC Antacid Adds To FDA’s API Impurity Concerns

US Zantac Sales And Distribution Continue As Sanofi Tests For NDMA

Amarin CEO: Consumers Have Heard About Omega-3 Heart Benefits ‘Too Long’

Sanofi Offloads Two German OTC Brands, New CEO Prepares To Make Mark

Sunscreen Test Lab Used Fewer Subjects Than Reported, US Prosecutors Allege

L’Oréal E-Commerce Growth Approaches 50%: ‘We Are Now Clearly A Digital-First Company’

Reckitt Invests In AI Symptom Checker To ‘Unlock Self-Care’

CBD Suits Challenge ‘THC-Free’ Claims After Users Fail Drug Tests; Plaintiffs Bar May Just Be Warming Up

GSK And Pfizer Assemble Consumer Healthcare Leadership Team As JV Closes

Orphan Drug Pricing And Reimbursement: Challenges To Patient Access

IXICO Targets Go-To Status In Neuro Data Analytics Space

FDA Announces More Actions On Drug-Coated Devices

Two More EU Notified Bodies But Not On Nando Yet

How To Pay For The New Wave Of Gene Therapies

Farxiga Data Change Heart Failure Treatment Outlook

Novo Nordisk’s Oral Rybelsus Priced On Par With Injectable GLP-1s, But Big Discounts May Be Needed

Roche: We’ve Abandoned Budgets And It’s Liberated Employees

US FDA Looks To Standardize Premarketing Safety Assessments

‘Project Orbis’ Oncology Pilot Eventually Will Target ‘Major Impact’ Applications

Patients’ Preferred Endpoints May Not Satisfy Regulatory Needs, US FDA Says

US FDA’s Office Of New Drugs Reorganization Approved, But Not Happening Overnight

EU Post-Market Clinical Follow Up: What Manufacturers Need To Know

FDA’s Quality System Regulation Is Mapped To International Standard ISO 13485 – And Vice Versa – In New Report From AAMI

Two First MDR Certificates Issued – Are Floodgates Open For Mass Certifications?

Commission Looks Set To Expand MDR Extension So Notified Bodies Can Focus On High-Risk Devices

EU Post-Market Clinical Follow Up: What Manufacturers Need To Know

European Commission Highlights Medtech Notified Bodies Giving It Cause For Concern

Why Deals Fail: The Reasons May Be Clinical, Economic Or Strategic

Novartis’s Zolgensma Loses EU Accelerated Assessment

Biotech CEOs: Can Scientist-Founders Remain In Charge?

Big Pharma CEOs Get Ready To Testify: Preparing For A No-Win Situation

An FDA Age-Based Predicate Policy Would Be Arbitrary, Reg Experts Complain

Sterilization Facility Shutdowns Could Spell Medical Device Shortage; FDA Urges Firms To Assess ‘Downstream Impacts’

Cannabis Industry Taking Legal Action Against EU Regulators Over CBD Novel Food Classification

Paying for Pharmaceutical Value: The Problem of a One-Size-Fits-All Definition

Going Generic: Big Brands Poised To Lose Marketing Exclusivity In The US In 2019

House Committee Hearing Shows How Talc/Asbestos Concerns Could Be Impetus For Cosmetics Reform

The Knowledge Within: An Interview With Merck KGaA’s R&D Chief

Breakthrough Designation Rescissions: Who Might US FDA Drop Next?

How Roche Won The Bidding Battle For Spark

Six Questions For McKinsey Executives On Pharma’s Digital Experience

OTC Marketing Awards 2019 Winners Announced – GSK Crowned Company Of The Year, Pfizer’s Viagra Takes Best Brand